Lys405
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys405  -  EPB41L3 (human)

Site Information
kFLtLGskFRysGRT   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 474985
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 7 , 8 )
Disease tissue studied:
colorectal cancer ( 4 ) , colorectal carcinoma ( 4 ) , gastric cancer ( 2 ) , lung cancer ( 1 ) , small-cell lung cancer ( 1 )
Relevant cell line - cell type - tissue:
DMS53 (pulmonary) ( 1 ) , HCT116 (intestinal) ( 4 , 6 , 7 , 8 ) , lung ( 1 ) , MKN-45 (gastric) ( 2 ) , NCI-H446 (pulmonary) ( 1 ) , NCI-H526 (pulmonary) ( 1 ) , NCI-H69 (pulmonary) ( 1 ) , NCI-H82 (pulmonary) ( 1 )

References 

1

Rikova K (2013) CST Curation Set: 20214; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

2

Rikova K (2012) CST Curation Set: 16030; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

3

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

4

Moritz A (2010) CST Curation Set: 9797; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

5

Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40
19608861   Curated Info

6

Li Y (2006) CST Curation Set: 1998; Year: 2006; Biosample/Treatment: cell line, HCT116/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

7

Li Y (2006) CST Curation Set: 1999; Year: 2006; Biosample/Treatment: cell line, HCT116/serum starved &'||' EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

8

Li Y (2006) CST Curation Set: 2000; Year: 2006; Biosample/Treatment: cell line, HCT116/serum starved &'||' EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info